Progenics Pharma (PGNX) Reports In-Line Q2 Loss of $0.08
More News related to PGNX
- Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
- Progenics Announces Wyeth Has Received RELISTOR Approval in Australia
- Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
- Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
- Progenics (PGNX) Reports Positive Interim Phase 2 Results for Novel HIV Therapy PRO 140
More News related to Earnings
- Van Nuys Airport's 80th Anniversary Event Honors Life-Saving Medical Flight Crews
- Microsemi Board Supports CEO; Governance Committee Reviewing Academic Credentials
- U.S. Must Own Up to Misdeeds, Says Grawemeyer Religion Winner
- CFIA/Warning: Allergy Alert-Undeclared Milk in Sunridge Farms Organic Dark Chocolate Almonds
- CFIA/Warning: Allergy Alert-Undeclared Milk in Sunridge Farms Organic Dark Chocolate Almonds
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reports a Q2 loss of $0.08, in-line with the analyst estimate of ($0.08). Revenues for the quarter were $28.6 million, versus the consensus of $29.52 million.
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat debilitating conditions and life-threatening diseases in the United States and internationally.
Related Categories
EarningsStocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
